Zacks Research lowered shares of InflaRx (NASDAQ:IFRX – Free Report) from a strong-buy rating to a hold rating in a research report report published on Tuesday,Zacks.com reports.
Other equities research analysts have also recently issued reports about the company. Wall Street Zen raised InflaRx from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Raymond James Financial raised InflaRx from an “outperform” rating to a “strong-buy” rating and increased their price target for the company from $7.00 to $9.00 in a research note on Wednesday, May 13th. HC Wainwright raised their price target on InflaRx from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald upped their price objective on InflaRx from $4.00 to $6.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $7.33.
View Our Latest Stock Report on IFRX
InflaRx Stock Performance
InflaRx (NASDAQ:IFRX – Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.04). On average, equities research analysts forecast that InflaRx will post -0.31 earnings per share for the current year.
Hedge Funds Weigh In On InflaRx
Several large investors have recently modified their holdings of the stock. Montanova Capital LLC raised its holdings in InflaRx by 189.1% during the 2nd quarter. Montanova Capital LLC now owns 22,933,910 shares of the company’s stock valued at $51,372,000 after buying an additional 15,000,000 shares during the period. Spruce Street Capital LP purchased a new position in InflaRx during the second quarter worth $11,988,924,000. ADAR1 Capital Management LLC bought a new position in InflaRx during the second quarter valued at $6,720,000. Bank of America Corp DE bought a new position in InflaRx during the third quarter valued at $3,316,000. Finally, Suvretta Capital Management LLC increased its position in InflaRx by 22.4% during the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after acquiring an additional 1,450,000 shares during the last quarter. Institutional investors own 42.39% of the company’s stock.
InflaRx Company Profile
InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.
Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.
See Also
- Five stocks we like better than InflaRx
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.com's FREE daily email newsletter.
